Lutetium Lu-177 Dotatate

Lutathera

Lutetium Lu-177 dotatate (Lutathera) is a radiopharmaceutical that combines a targeting peptide with a therapeutic radioactive atom — a strategy called peptide receptor radionuclide therapy, or PRRT. The targeting portion is a somatostatin analog (DOTATATE, related to octreotide) that binds tightly to somatostatin receptors, particularly subtype 2 (SSTR2). Many neuroendocrine tumors (NETs) express these receptors in abundance on their surface. Attached to the peptide through a chelator (DOTA) is lutetium-177, a radionuclide that emits beta particles. When the peptide docks onto SSTR2 on a tumor cell, it carries the radioactive payload right to the cancer, where the short-range beta radiation damages the tumor's DNA — delivering a concentrated dose to receptor-positive cells while relatively sparing surrounding tissue. Lutathera is approved for the treatment of somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults, a group that includes tumors of the small intestine, pancreas, and related sites. It is given as a series of intravenous infusions spaced weeks apart, and — because the kidneys are the organ most at risk from filtered radioactivity — it is co-administered with an amino acid solution that protects the kidneys by reducing renal reuptake of the peptide. Because this is targeted radiation, its use is confined to specialized nuclear-medicine and oncology centers with radiation-safety protocols. Whether a patient is a candidate is determined in part by imaging that confirms the tumor expresses somatostatin receptors (for example a gallium-68 dotatate PET scan). Notable considerations include kidney protection, effects on blood counts (bone-marrow suppression), and, rarely, secondary blood cancers over the long term. Lutetium Lu-177 dotatate is an approved prescription therapy administered only under specialist supervision — it is not a research or self-administered peptide.